Company Analysis
Sign in

CytoMed Therapeutics Limited (GDTC)

Nasdaq: GDTC · Pharmaceutical Preparations · 1 Commonwealth Lane, SG · filing with the SEC since 2021
Full chart Alerts Compare
Grade5.5
◀ Past 6.0● Present 5.8▶ Future 5.0
5 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Income statement, as filed

In Singapore dollars (SGD), as filed; per-share figures in Singapore dollars; share counts. The fiscal year ends in December.
Income statement, by fiscal year, newest first
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period endingDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020
Report filedMar 31, 2026Apr 28, 2025Apr 22, 2024May 1, 2023··
Revenue324,38769,501····
Research and development2,217,4951,909,5191,589,6931,522,7651,090,6231,038,091
Finance costs20,90620,31351,282125,175117,696105,519
Interest income123,898317,670285,7192,0973,369·
Share of profit of equity-method investments-6,39113,765-31,198-33,5462,719·
Other gains and losses140,318297,545-492,910-1,116,6223,185-573,856
Income before income taxes-3,996,336-2,521,861-4,132,517-3,129,812-2,051,903-1,935,626
Income tax expense··6531,640··
Net income-3,996,336-2,521,861-4,133,170-3,131,452-2,051,903-1,935,626
Net income to non-controlling interests·-5,163-274-243-253-186
Net income to shareholders-3,980,457-2,516,698-4,132,896-3,131,209-2,051,650-1,935,440
Earnings per share, basic-0.34-0.22-0.39-0.40-0.30·
Earnings per share, diluted-0.34-0.22-0.39-0.40-0.30-0.33
Weighted average shares, basic11,647,22511,539,83410,630,3447,915,1016,934,824·
Weighted average shares, diluted11,647,22511,539,83410,630,3447,915,1016,934,8245,897,651
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it soldifrs-full:Revenue
Research and development spent on inventing what it sells nextifrs-full:ResearchAndDevelopmentExpense
Finance costs what its borrowing costifrs-full:FinanceCosts
Interest income what its cash and investments earnedifrs-full:RevenueFromInterest
Share of profit of equity-method investments its share of companies it partly ownsifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
Other gains and losses gains and costs outside the businessifrs-full:OtherGainsLosses
Income before income taxes profit before taxifrs-full:ProfitLossBeforeTax
Income tax expense tax charged on the period's profitifrs-full:IncomeTaxExpenseContinuingOperations
Net income the whole group's profit, minority holders' share includedifrs-full:ProfitLoss
Net income to non-controlling interests the share that belongs to minority holdersifrs-full:ProfitLossAttributableToNoncontrollingInterests
Net income to shareholders the profit or loss that belongs to the company's shareholdersifrs-full:ProfitLossAttributableToOwnersOfParent
Earnings per share, basic net income per share outstandingifrs-full:BasicEarningsLossPerShare
Earnings per share, diluted net income per share, counting every share that could be issuedifrs-full:DilutedEarningsLossPerShare
Weighted average shares, basic the average count of shares outstandingifrs-full:WeightedAverageShares
Weighted average shares, diluted the average count with every share that could be issuedifrs-full:AdjustedWeightedAverageShares
SI Assistanton GDTC · research, not advice